文献速递淋巴瘤白血病

沉默HDAC6作为慢性淋巴细胞白血病的治疗靶点

Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia.
PubMed 文献 · Blood Adv · 2018-01-01

慢性淋巴细胞白血病(CLL)仍不可治愈,耐药与复发是重要挑战。本研究首次发现HDAC6在CLL患者样本、细胞系及euTCL1转基因小鼠中表达上调,遗传沉默HDAC6使euTCL1小鼠获得生存获益;HDAC6抑制剂ACY738可抑制CLL B细胞增殖、延迟发病并增敏凋亡,与伊布替尼联用显示协同杀伤并改善总体生存。

要点

  • HDAC6在CLL患者样本、细胞系及euTCL1小鼠中表达上调。
  • 遗传沉默HDAC6使euTCL1小鼠获得生存获益。
  • ACY738与伊布替尼联用对CLL细胞系显示协同杀伤,体内较单药改善总体生存。

核心结论

  • 首次在临床前CLL模型中证明选择性HDAC6抑制具有治疗效力,并为HDAC6抑制剂单用或联合Bruton酪氨酸激酶抑制用于CLL治疗的临床开发提供依据。

研究设计与样本

  • 临床前研究,比较CLL患者样本、细胞系及euTCL1转基因小鼠与正常对照中HDAC6的表达,并在euTCL1衰老与过继转移模型中评价HDAC6抑制剂ACY738。

主要发现

  • HDAC6在CLL患者样本、细胞系及euTCL1转基因小鼠中表达较正常对照上调。
  • 遗传沉默HDAC6使euTCL1小鼠获得生存获益。
  • 在euTCL1衰老与过继转移模型中给予异构体特异性HDAC6抑制剂ACY738,可阻止CLL B细胞增殖、通过干扰B细胞受体信号延迟疾病发生并使CLL B细胞对凋亡增敏。
  • ACY738与伊布替尼联用对CLL细胞系显示协同细胞杀伤,在体内较任一单药改善总体生存。

局限性

  • 上述结果来自临床前CLL模型,作者提出HDAC6抑制剂单用或联合Bruton酪氨酸激酶抑制用于CLL治疗临床开发的依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although the treatment paradigm for chronic lymphocytic leukemia (CLL) is rapidly changing, the disease remains incurable, except with allogeneic bone marrow transplantation, and resistance, relapsed disease, and partial responses persist as significant challenges. Recent studies have uncovered roles for epigenetic modification in the regulation of mechanisms contributing to malignant progression of CLL B cells. However, the extent to which epigenetic modifiers can be targeted for therapeutic benefit in CLL patients remains poorly explored. We report for the first time that expression of epigenetic modifier histone deacetylase 6 (HDAC6) is upregulated in CLL patient samples, cell lines, and euTCL1 transgenic mouse models compared with HDAC6 in normal controls. Genetic silencing of HDAC6 conferred survival benefit in euTCL1 mice. Administration of isoform-specific HDAC6 inhibitor ACY738 in the euTCL1 aging and adoptive transfer models deterred proliferation of CLL B cells, delayed disease onset via disruption of B-cell receptor signaling, and sensitized CLL B cells to apoptosis. Furthermore, coadministration of ACY738 and ibrutinib displayed synergistic cell kill against CLL cell lines and improved overall survival compared with either single agent in vivo. These results demonstrate for the first time the therapeutic efficacy of selective HDAC6 inhibition in preclinical CLL models and suggest a rationale for the clinical development of HDAC6 inhibitors for CLL treatment, either alone or in combination with Bruton tyrosine kinase inhibition.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Maharaj K, Powers JJ, Achille A, et al. Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia. Blood Adv. 2018. PMID: 30425065. doi:10.1182/bloodadvances.2018020065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。